FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote

If FDA had accepted Forest's proposed revised indication for Daxas (roflumilast), the chronic obstructive pulmonary disease drug could have yielded a different outcome from the Pulmonary-Allergy Drugs Advisory Committee